10 ENGLISH BOOKS RELATING TO «ALKYLATING AGENT»
Discover the use of
alkylating agent in the following bibliographical selection. Books relating to
alkylating agent and brief extracts from same to provide context of its use in English literature.
1 he rate of quaternization of tertiary amines is influenced by three general
variables-structure of the amine, structure of the alkylating agent, and reaction
conditions (temperature, solvent, etc.). Comparative information relating to the
structure ...
Thomas H. Applewhite, 1991
In effect, the alkylating agent transfers a carbocation (R+) to the nucleophile.
Alcohols, amines, thiols, and other nucleophilic functionalities are ubiquitous in
biological molecules. An organic chemist might carry out a methylation with an
agent ...
P. David Josephy, Bengt Mannervik, 2006
3
Essential Cancer Pharmacology: The Prescriber's Guide
Oncology Class Generic Name Brand Name Page Numbers Alkylating Agent
bendamustine Treanda 42–43 Alkylating Agent busulfan Busulfex, Myleran 57–
58 Alkylating Agent carboplatin Paraplatin 61–62 Alkylating Agent carmustine
BCNU ...
Sara K. Butler, Ramaswamy Govindan, 2010
4
The Washington Manual Hematology and Oncology Subspecialty ...
CONTINUED Chemotherapy agent Classification Oxaliplatin ( Eloxatin)
Alkylating agent ( platinum ) Alkylating agent (ethylen- imine) Alkylating agent (
miscellaneous) Temozolomide (Temo- Alkylating agent (miscella- dar) neous)
TABLE 17-1.
Giancarlo Pillot, Marcia Chantler, 2004
Although the modification sites are the same, the percentage of modification at
each site depends on the specific alkylating agent. The damage resulting from
bulky alkylating agents is generally removed by NER, but many less bulky ...
Wolfram Siede, Paul W. Doetsch, 2005
6
Blueprints Notes and Cases, Pharmacology
Cisplatin, a platinum alkylating agent, and paclitaxel, a taxane, are two of the
most effective drugs for ovarian cancer. Cisplatin is known to be the most
emetogenic chemotherapy agent. It is also known to cause neuropathy,
nephrotoxicity, ...
Katherine Y. Yang, Larissa R. Graff, Aaron B. Caughey, 2004
7
Step-Up to USMLE Step 1: A High-Yield, Systems-Based Review ...
... thrombocytopenia; megaloblastic anemia Cyclophosphamide [Cytoxan] Cell
cycle nonspecific agent—alkylating agent → crosslinks DNA strands →
decreases DNA synthesis and prevents cell division → destroys proliferating
lymphoid cells ...
... mTOR inhibitor PDGFR þ alkylating agent FTI þ alkylating agent VEGF þ
topoisomerase I inhibitor MMP þ alkylating agent HDAC inhibitor þ alkylating
agent EGFR þ alkylating agent EGFR þ alkylating agent EGFR þ alkylating agent
Integrin ...
9
Havard's Nursing Guide to Drugs
(intermittentalkylating agent therapy) 40% of alkylating agent dose orally 2 hours
before alkylating agent therapy andrepeated at 2and 6hours OR • initially 20% of
alkylating agent dose IVwithalkylating agenttherapy, followed by oral dose ...
Mutations of TP53 were observed in 21 of 77 unselected adults (27%) with
treatment-related AML/MDS, with alkylating agent exposure in 19 of the 21.211
Mutations of TP53 are also common in leukemia and MDS following multiagent
ovarian ...
10 NEWS ITEMS WHICH INCLUDE THE TERM «ALKYLATING AGENT»
Find out what the national and international press are talking about and how the term
alkylating agent is used in the context of the following news items.
Dr. Philip on Evofosfamide for Pancreatic Cancer
It then releases bromo isophosphoramide mustard (Br-IPM), a potent DNA alkylating agent. This kills tumor cells by forming DNA crosslinks, ... «OncLive, Jul 15»
SeeThruEquity Issues Update on DelMar Pharmaceuticals …
VAL-083 is a first-in-class small molecule with a novel alkylating agent that has been assessed in over 40 National Cancer Institute-sponsored ... «Baystreet.ca, Jun 15»
Bayer to Present New Data on Copanlisib in Hematological …
... relapsed indolent NHL who have received at least one prior line of treatment, including rituximab and an alkylating agent (NCT02367040). «SYS-CON Media, Jun 15»
DelMar Pharmaceuticals Invited to Present at The World NSCLC …
VAL-083 is a "first-in-class" bi-functional alkylating agent mediating inter-strand DNA crosslinks at N7 of guanine. VAL-083 has previously ... «Stockhouse, Jun 15»
ASCO: Triple Agent Tx Thwarts CLL Progress
... against the protein CD20, which is primarily found on the surface of B cells, and bendamustine is a nitrogen mustard alkylating agent. «MedPage Today, May 15»
Threshold Pharmaceuticals Presents Encouraging Preliminary …
... class of immunomodulators), proteasome inhibitors (including bortezomib), dexamethasone, and at least one conventional alkylating agent. «MarketWatch, May 15»
DelMar Pharmaceuticals Presents Additional Data on the Potential …
VAL-083 is an alkylating agent whose cytotoxic anti-cancer mechanism is believed to be via the formation of DNA crosslinks at N7 position of ... «Stockhouse, May 15»
Parenthood for Childhood Hodgkin Lymphoma Survivors
... cyclophosphamide in cumulative doses up to 6,000 mg/m², alkylating agent dose scores of 1 to 5, therapy group based on disease stage at ... «Cancer Network, May 15»
DelMar Pharmaceuticals Presents Promising Preclinical Data on …
VAL-083 is an alkylating agent causing DNA crosslinks at N7 position of guanine. Because VAL-083's N7 adducts appear not to be subject to ... «PR Newswire, Apr 15»
Health Canada Approves New Indication for Xtandi
... with relapsed iNHL who have received at least one prior line of treatment, including rituximab and an alkylating agent (NCT02367040). «The Cancer Letter Publications, Apr 15»
